Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

January 31, 2013

Study Completion Date

December 31, 2013

Conditions
Pancreatic Cancer
Interventions
DRUG

Erlotinib

Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.

DRUG

gemcitabine

The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.

Trial Locations (2)

95817

University of California Davis Cancer Center, Sacramento

90089-9181

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

lead

University of California, Davis

OTHER